Last updated: 2026-09-08 05:24:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
ProMIS Neurosciences Inc. (PMN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $12.47, with a market capitalization of $112.99M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.27 to $27.40. This page covers its latest market performance, valuation, price trends and company information.
$112.99M | |
$13.03 | |
$350.00 | |
$6.27 | |
$12.90 | |
23.15K | |
84.56K | |
-- | |
$27.40 | |
$6.27 | |
-- | |
-- |
ProMIS Neurosciences Inc. (PMN) last closed at $12.90 as of 2026-09-04 23:09:00, unchanged from the previous close of $12.90.
During the latest regular trading session, PMN traded between $6.27 and $350.00, with a volume of 23.15K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, ProMIS Neurosciences Inc. (PMN) moved from $13.99 to $12.47, representing a decline of 10.86% ($1.52).
The stock traded between $12.47 and $15.19 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 41.10 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 29.3%
PMN is currently trading at $12.47, placing it 29.3% of the way from its 52-week low of $6.27 to its 52-week high of $27.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 11 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of ProMIS Neurosciences Inc. (PMN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.